ReviewCancer immunity2009
Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma.
Review in Cancer immunity, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03447678 (Phase II Study to Test Pembrolizumab), which is not on this map. Cited by 103 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase II Study to Test Pembrolizumab (MK-3475) in First Line Treatment of Advanced NSCLC Patients With PD-L1 Low Tumors (<50%)_ PEOPLE TRIAL (Pembrolizumab in Pd-L1 Low Expressors).
Who cites it
103 citing papers in PubMed, 2 syntheses or guidelines pooled it, 199 citations in OpenAlex.
- Imaging of tumour response to immunotherapy.European radiology experimental · 2020Pooled it
- Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival.Genome research · 2014Pooled it
- Low-dose interferon-alpha preconditioning and adoptive cell therapy in patients with metastatic melanoma refractory to standard (immune) therapies: a phase I/II study.Journal for immunotherapy of cancer · 2020Trial
- A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma.Annals of oncology : official journal of the European Society for Medical Oncology · 2015Trial
- A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma.Journal of translational medicine · 2011Trial
- Successful treatment of metastatic melanoma by adoptive transfer of blood-derived polyclonal tumor-specific CD4+ and CD8+ T cells in combination with low-dose interferon-alpha.Cancer immunology, immunotherapy : CII · 2011Trial
- Immunohistochemical Predictors in Head and Neck Mucosal Melanoma.Head and neck pathology · 2026Article
- Review
- A Consolidated Review of Contemporary Targeted and Immunotherapeutic Options for Melanoma.Biomedicines · 2025Review
- ImmuNet: a segmentation-free machine learning pipeline for immune landscape phenotyping in tumors by multiplex imaging.Biology methods & protocols · 2025Article
- Outcomes of patients with advanced solid tumors who discontinued immune-checkpoint inhibitors: a systematic review and meta-analysis.EClinicalMedicine · 2024Article
- Cancer mRNA vaccines: clinical advances and future opportunities.Nature reviews. Clinical oncology · 2024Review
- Evaluation of tumour infiltrating lymphocytes in luminal breast cancer using artificial intelligence.British journal of cancer · 2023Article
- Modeling tumor size dynamics based on real-world electronic health records and image data in advanced melanoma patients receiving immunotherapy.CPT: pharmacometrics & systems pharmacology · 2023Article
- Invasive Cutaneous Melanoma: Evaluating the Prognostic Significance of Some Parameters Associated with Lymph Node Metastases.Medicina (Kaunas, Lithuania) · 2023Article
- An update on methods for detection of prognostic and predictive biomarkers in melanoma.Frontiers in cell and developmental biology · 2023Review
- SPARTIN: a Bayesian method for the quantification and characterization of cell type interactions in spatial pathology data.Frontiers in genetics · 2023Article
- SPP1 is a prognostic related biomarker and correlated with tumor-infiltrating immune cells in ovarian cancer.BMC cancer · 2022Article
- The Association of CD8+ Cytotoxic T Cells and Granzyme B+ Lymphocytes with Immunosuppressive Factors, Tumor Stage and Prognosis in Cutaneous Melanoma.Biomedicines · 2022Article
- PPP2R2D Suppresses Effector T Cell Exhaustion and Regulatory T Cell Expansion and Inhibits Tumor Growth in Melanoma.Journal of immunology (Baltimore, Md. : 1950) · 2022Article
43 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumors contain variable numbers of lymphocytes, referred to as tumor infiltrating lymphocytes (TILs). In melanoma, the intensity of this lymphocytic infiltrate is believed to correlate with outcome, though there is some debate about the applicability of this finding for all melanomas. Much research has gone into classifying TILs with respect to antigen receptor structure and the antigen to which melanoma-specific T cells react. However, these studies for the most part did not immunophenotype TILs, and recent data has revealed that the composition of tumoral lymphocytes is not homogenous, but rather represents varying contributions from many lymphocytic subsets. Furthermore, the function of TILs is often compromised as a result of the accumulation of immunoregulatory cells and various tumor escape mechanisms. These recent insights stress the need to collect more data on the composition and function of TIL infiltrates before definitive conclusions about the prognostic significance of TILs can be drawn. Advances in immunology have also facilitated the development of immunotherapeutic strategies, examples of which will be discussed with a special emphasis on blocking antibodies against CTLA-4, which are prototypical immunotherapeutic agents. This flurry of novel "biological" therapies will undoubtedly complicate our already incomplete understanding of TIL immunobiology as each of these agents has the potential to uniquely distort the series of immunological events which normally occur in untreated melanoma. Therefore, considerable research is needed to better elucidate the function and prognostic significance of TILs in both untreated melanoma and tumors treated with "biological" therapy.
Indexed as
Identifiers
19338264PMC2935762W2112387900What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.